F-star enters license deal with Takeda for a cancer immune therapy antibody

Jul. 20, 2022 9:55 AM ETF-star Therapeutics, Inc. (FSTX), TAKBy: Anuron Mitra, SA News Editor

Close up of holding hands

Kelvin Murray

  • F-star Therapeutics (NASDAQ:FSTX) on Wednesday said it had entered into a licensing agreement with Japanese pharmaceutical major Takeda (NYSE:TAK) to develop a cancer immune therapy.
  • As per the terms of the deal, FSTX will grant Takeda a worldwide license to research, develop and commercialize an antibody against a cancer target using F-star's (FSTX) Fcab and mAb2 platforms.
  • FSTX will get an upfront license fee of $1M, and will be eligible to get up to $40M in milestone payments.
  • FSTX stock was marginally higher in early trading, while U.S.-listed shares of TAK were -0.6% at $14.58.

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.